<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005209</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00100887</org_study_id>
    <nct_id>NCT04005209</nct_id>
  </id_info>
  <brief_title>Ketamine Infusion for Sickle Cell Pain Crisis</brief_title>
  <official_title>Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively study the efficacy of low dose ketamine
      infusions in treating patients who are admitted to the hospital with a sickle cell pain
      crisis. Participants will be prospectively randomized in unblinded fashion in the first 12 to
      24 hours of an inpatient admission for sickle cell pain crisis to receive pain management
      without ketamine infusion (Group A) versus pain management that includes low-dose ketamine
      infusion starting at 0.2mg/kg/h (Group B). The effect of this intervention on various pain
      management and healthcare utilization outcome measures will be recorded and analyzed to
      determine whether or not there is a measurable benefit of using ketamine infusions in this
      patient population.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage reduction in grand mean opioid consumption from 0 to 72 hours</measure>
    <time_frame>baseline, 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in grand mean pain score using the 11-point visual analog scale</measure>
    <time_frame>baseline, 72 hours</time_frame>
    <description>Using standard 11-point visual analog pain scale, ranging from 0 = no pain to 10 = worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from inpatient admission to readiness for discharge</measure>
    <time_frame>Upon discharge from the hospital (an average of 1 week)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day hospital readmission rate</measure>
    <time_frame>30 days from discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Anemia; Sickle-Cell, With Crisis</condition>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>Pain management without ketamine infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pain management without ketamine infusion. No other restrictions on pain management or medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pain management with ketamine infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pain management that includes a ketamine infusion. No other restrictions on pain management or medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.</description>
    <arm_group_label>Pain management with ketamine infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pain management</intervention_name>
    <description>Pain management</description>
    <arm_group_label>Pain management with ketamine infusion</arm_group_label>
    <arm_group_label>Pain management without ketamine infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a pre-existing/known diagnosis of sickle cell disease, prior to the current
             presentation

          -  Admitted to Duke University Hospital with a clinical diagnosis of sickle cell crisis

          -  Are at least 18 years old at time of admission

          -  Have been admitted to any hospital for sickle cell pain crisis at least twice in the
             last year

          -  Have documented severe pain at time of admission, requiring intravenous opiates

          -  Must be able to speak English

        Exclusion Criteria:

          -  Are greater than 70 years old at time of admission

          -  Carry a diagnosis of cirrhosis, elevated intracranial pressure, elevated intraocular
             pressure, active coronary artery disease, and psychiatric disorders with history of
             psychosis

          -  Are pregnant or breastfeeding

          -  Are concomitantly admitted for another medical or surgical problem in addition to
             sickle cell pain crisis

          -  Have been admitted to any hospital for a sickle cell pain crisis greater than 10 times
             in the last year

          -  Were admitted to any hospital for sickle cell pain crisis within the last 30 days

          -  Are able to fully and properly consent for their own medical care, with no
             restrictions or limitations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neil Ray, MD</last_name>
    <phone>9196811924</phone>
    <email>neil.d.ray@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David W Creighton, MD</last_name>
    <email>david.creighton@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David W Creighton, MD</last_name>
      <email>david.creighton@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Neil Ray, MD</last_name>
      <email>neil.d.ray@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David W Creighton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nirmish Shah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neil Ray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milly Rambhia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Gauthier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Horazeck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Intravenous Infusions</keyword>
  <keyword>Anemia; Sickle-Cell, with Crisis</keyword>
  <keyword>Acute Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

